RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

Corey A Carter; Bryan T Oronsky; Scott Z Caroen; Jan J Scicinski; Aiste Degesys; Michelle M Kim; Arnold L Oronsky; Harry Lybeck; Pedro Cabrales; Neil Oronsky; Tony Reid; Joseph Roswarski; Christina Brzezniak

doi:10.1159/000444631

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.

Authors

Affiliations

¹ Walter Reed National Military Medical Center, Murtha Cancer Center, Bethesda, Md., USA.
² EpicentRx Inc., Mountain View, Calif., USA.
³ Department of Radiation Oncology, University of Michigan, Ann Arbor, Mich., USA.
⁴ InterWest Partners, Menlo Park, Calif., USA.
⁵ Department of Physiology, University of Helsinki, Helsinki, Finland.
⁶ Department of Bioengineering, University of California San Diego, La Jolla, Calif, USA.
⁷ CFLS Data, Mountain View, Calif., USA.
⁸ Moores Cancer Center, University of California San Diego, La Jolla, Calif., USA.

Abstract

RRx-001 is a pan-active, systemically nontoxic epigenetic inhibitor under investigation in advanced non-small cell lung cancer, small-cell lung cancer and high-grade neuroendocrine tumors in a Phase II clinical trial entitled TRIPLE THREAT (NCT02489903), which reexposes patients to previously effective but refractory platinum doublets after treatment with RRx-001. The purpose of this case study is first to report a partial response to carboplatin and etoposide in a patient with small-cell lung cancer pretreated with RRx-001, indicating episensitization or resensitization by epigenetic mechanisms, and second to discuss the literature related to small-cell lung cancer and episensitization.

Keywords: Epigenetic; Episensitization; Platinum doublets; Resensitization; Resistance; Small-cell lung cancer.

Publication types

Case Reports